Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3488 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 27 28 29 ... 33 34 35  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
MCG Motion Capture–SEVERAL: investment, 201910– PLANNED financing round Series A $15m 2019-10-22
Arcutis Biotherapeutics–HBM: investment, 201910 financing round Series C totalling $94.5m incl new + lead investor HBM Healthcare Investments 2019-10-21
Arcutis Biotherapeutics–SEVERAL: investment, 201910 financing round Series C $94.5m led by HBM Healthcare Investments 2019-10-21
Danaher–Sartorius: investment, 201910– acquisition $750m three life science businesses by Sartorius part of regulatory clearance for GE/Danaher deal 2019-10-21
Avacta–SEVERAL: investment, 201910– proposed placing + subscription up to £9m with 59.8m nrew ordinary shares at 15p/share 2019-10-18
Plexium–Merck (DE): investment, 201910 financing round Series A totalling $28m incl co-investor M Ventures 2019-10-17
Plexium–SEVERAL: investment, 201910 financing round Series A $28m co-led by DCVC Bio + The Column Group 2019-10-17
Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund 2019-10-17
Versameb–SEVERAL: investment, 201910 seed C financing round CHF6.4m bringing total capital raised to CHF11.8m 2019-10-17
Healx–Amadeus Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Amadeus Capital Partners 2019-10-16
Healx–Balderton Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Balderton Capital 2019-10-16
Healx–btov Partners: investment, 201910 financing round Series B totalling $56m incl new + co-investor btov Partners 2019-10-16
Healx–PERSON: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Jonathan Milner 2019-10-16
Healx–SEVERAL: investment, 201910 financing round Series B $56m led by new investor Atomico 2019-10-16
Abalos Therapeutics–Boehringer: investment, 201910 financing round Series A totalling €12m invl co-lead investor BIVF 2019-10-15
Abalos Therapeutics–High-Tech Gründerfonds: investment, 201910 financing round Series A totalling €12m incl co-investor HTGF 2019-10-15
Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-investor NRW.BANK 2019-10-15
Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-lead investor Gründerfonds Ruhr 2019-10-15
Abalos Therapeutics–SEVERAL: investment, 201910 financing round Series A €12m co-led by BIVF + Gründerfonds Ruhr 2019-10-15
Abalos Therapeutics–Trophic Communications: public relations, 201910 service existent by Trophic 2019-10-15
CRISPR Therapeutics–KSQ Therapeutics: CRISPR-based cell therapy, 201910– cross-licensing €na genome editing + CAR-T cell therapy IP 2019-10-15
Biocon–Evotec: biosimilars, 201910– license €na to Biocon Biologics for pre-clinical biosimilar asset of Just-Evotec Biologics 2019-10-10
FloDesign Sonics–Merck (DE): investment, 201910 acquisition €na by Merck 2019-10-10
Celmatix–Evotec: drug discovery services, 201910– collab €na developm pre-clinical programs for reproductive women’s health 2019-10-09
Parexel–Roivant: healthcare informatics, 201910– collab with Datavant multi-year strategic alliance integration of real-world with clinical trial data 2019-10-09
Bayer–RIKEN: drug discovery, 201910– strategic collaboration incl drug target discovery of Bayer Open Innovation Center Japan + RIKEN Innovation 2019-10-08
GSK–Lyell Immunopharma: cancer cell therapy, 201910–202409 collab 5y developm of technologies to improve cancer cell therapies 2019-10-08
Vivoryon–MC Services: public relations, 201910 service existent by MC Services 2019-10-08
Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG 2019-10-08
Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys 2019-10-08
Vivoryon–Trophic Communications: public relations, 201910 service existent by Trophic 2019-10-08
4SC–SEVERAL: investment, 201910–201911 capital increase €22.4m net €22m with 10.65m new shares at €2.1/share with subscription rights 2019-10-07
4SC–Strüngmann Group: investment, 201910 capital increase totalling €22.4m net €22m incl subscription rights for Santo Holding + ATS 2019-10-07
Dalhousie Univ–Thermo Fisher: mass spectrometer, 201910 supply C$1.3m of Orbitrap Fusion MS system to MS + Proteomics Core Faclity 2019-10-07
Illumina–Qiagen: sequencing-based IVD tests, 201910–2034 collab 15y strategic alliance combining sequencing technology + assays + automation + s/w 2019-10-07
Lundbeck–LeadXPro: drug discovery services, 201910– collab structural proteomics services using X-ray + cryo-EM for small molecule drug discovery 2019-10-07
Rentschler–Sumitomo: biologics contract manufacturing, 201910– collab expansion SPI supports marketing + delivery of Rentschler CDMO services in Japan 2019-10-04
Aeovian Pharmaceuticals–Apollo Health Ventures: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Apollo HV 2019-10-03
Aeovian Pharmaceuticals–Evotec: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Evotec 2019-10-03
Aeovian Pharmaceuticals–SEVERAL: investment, 201910 financing round Series A $37m led by VenBio + Sofinnova Investments 2019-10-03
Aeovian Pharmaceuticals–Sofinnova: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor Sofinnova Investments 2019-10-03
Aeovian Pharmaceuticals–VenBio: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor VenBio Partners 2019-10-03
Freiberg Instruments–Bruker: investment, 201910 acquisition €na of Magnettech EPR business by Bruker 2019-10-02
Cellectis–Lonza: cell therapy contract manufacturing, 201910– supply UCART cell therapy candidates by Lonza in Geleen (NL) 2019-10-01
Eisai–Numab: antibody cancer drug, 201910– collab + license option ww excl developing multi-specific Abs using MATCH platform 2019-10-01
Novartis–Microsoft: artificial intelligence, 201910– collab strategic multiyear AI for drug RnD + commercialisation 2019-10-01
Creoptix–SEVERAL: investment, 201909 financing round Series 1st closing CHF8m incl investors Swisscanto Invest + Waters 2019-09-30
Creoptix–Waters: investment, 201909 financing round Series 1st closing totalling CHF8m incl existing + co-investor Waters Corp 2019-09-30
Creoptix–Zürcher Kantonalbank: investment, 201909 financing round Series 1st closing totalling CHF8m incl new + lead investor Swisscanto Invest 2019-09-30
STipe Therapeutics–SEVERAL: investment, 201909 financing round Series A €20m co-led by Arix Bioscience + Novo Holdings 2019-09-30
Roper Technologies–AMETEK: investment, 201909– acquisition $925m in cash of Gatan Inc from Roper Technologies by AMETEK 2019-09-27
T3 Pharmaceuticals–Boehringer: investment, 201909 2nd financing round totalling CHF12m incl new investor BIVF 2019-09-26
T3 Pharmaceuticals–Reference Capital: investment, 201909 2nd financing round totalling CHF12m incl new investor Reference Capital SA 2019-09-26
T3 Pharmaceuticals–SEVERAL: investment, 201909 2nd financing round CHF12m incl new investors BIVF + Reference Capital SA 2019-09-26
Tacalyx–Boehringer: investment, 201909 seed financing round totalling €7m incl co-lead investor BIVF 2019-09-25
Tacalyx–Creathor Ventures: investment, 201909 seed financing round totalling €7m incl co-investor Creathor Ventures 2019-09-25
Tacalyx–Eurazeo: investment, 201909 seed financing round totalling €7m incl co-investor Idinvest Partners 2019-09-25
Tacalyx–Eurazeo: investment, 201909 seed financing round totalling €7m incl co-lead investor Kurma Partners 2019-09-25
Tacalyx–Germany (govt): investment, 201909 seed financing round totalling €7m incl co-investor Coparion 2019-09-25
Tacalyx–High-Tech Gründerfonds: investment, 201909 seed financing round totalling €7m incl co-investor HTGF 2019-09-25
Tacalyx–Huntsworth: public relations, 201909 service existent by Citigate Dewe Rogerson 2019-09-25
Tacalyx–Max Planck: antibody discovery technology, 201909c license to plaQorm technology of MPI of Colloids + Interfaces from Max Planck Innovation 2019-09-25
Tacalyx–SEVERAL: investment, 201909 seed financing round €7m co-led by BIVF + Kurma Partners 2019-09-25
Addex–SEVERAL: investment, 201909– filing of Nadaq lisiting of ADSs (without proposing to register any new issuance of secutiries) 2019-09-24
Takeda–Evotec: drug discovery services, 201909– collab strategic multi-year across multiple indications 2019-09-24
AC Immune–LaVoieHealthScience: public relations, 201909– supply service existent US media relations by LHS 2019-09-20
AC Immune–LifeSci: public relations, 201909 supply service existent European investor + media relations by LifeSci Advisors 2019-09-20
Boehringer–Inflammasome: drug delivery technology, 201909– co-developm + license up to 3 retinal disease therapies using IVT drug delivery 2019-09-20
Bruker–Murdoch Univ: analytical technologies, 201909– collab strategic alliance with ANPC incl MS + NMR for phenomics research 2019-09-20
Murdoch Univ–Bruker: NMR spectrometer, 201909 supply NMR FoodScreener 2019-09-20
Oncimmune–IPF Partners: credit, 201909– 202309 credit facility €8.5m four year incl warrant for 2m new ordinary shares IPF Management SA 2019-09-20
Novigenix–BioLizard: bioinformatics, 201909– collab developm of AI-based bioinformatics algorithm to support developm of tests for LITOseek platform 2019-09-19
Themis Bioscience–Farallon Capital: investment, 201909 financing round Series D totalling €40m incl new + co-lead investor Farallon Capital 2019-09-18
Themis Bioscience–Hadean Ventures: investment, 201909 financing round Series D totalling €40m incl new + co-lead investor Hadean Ventures 2019-09-18
Themis Bioscience–SEVERAL: investment, 201909 financing round Series D €40m co-led by Farallon Capital + Hadean Ventures 2019-09-18
Versantis–SEVERAL: investment, 201909 financing round Series B CHF16m led by Swisscanto Invest by ZKB 2019-09-18
Bayer–Informed Data Systems: digital health, 201909– collab + licensing agreem $10m developm + commercialisaing of One Drop technology platform 2019-09-17
Informed Data Systems–Bayer: investment, 201909 Series B financing incl $20m from Bayer 2019-09-17
Life Healthcare Group–AC Immune: PET tracer, 201909 collab existent developm Tau PET tracer PI-2620 with Life Molecular Imaging 2019-09-17
Versantis–Halsin Partners: public relations, 201909 service existent by Halsin Partners 2019-09-17
Belyntic–Berlin (govt): investment, 201909 seed financing round totalling €1.3m incl lead investor IBB 2019-09-16
Belyntic–High-Tech Gründerfonds: investment, 201909 seed financing round totalling €1.3m incl co-investor HTGF 2019-09-16
Belyntic–PERSON: investment, 201909 seed financing round totalling €1.3m incl co-investor business angel Till Knorr 2019-09-16
Belyntic–SEVERAL: investment, 201909 seed financing round €1.3m led by IBB + incl HTGF + business angel Till Knorr 2019-09-16
GenomSys–Club degli Investitori: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Club degli Investitori 2019-09-16
GenomSys–Dolby Family Ventures: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Dolby Family Ventures 2019-09-16
GenomSys–Elysia Capital: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Elysia Capital 2019-09-16
GenomSys–Preon Capital: investment, 201909 financing round Series A totalling CHF9.3m incl lead investor Preon Capital 2019-09-16
GenomSys–Pygar: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Pygar family office 2019-09-16
GenomSys–SEVERAL: investment, 201909 financing round Series A CHF9.3m led by Preon Capital 2019-09-16
GenomSys–Susman Ventures: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Susman Ventures 2019-09-16
OTHER–Curetis: molecular diagnostics, 201909– collab RnD + option for NGS-based antibiotic resistance testing of Ares Genetics with global IVD firm 2019-09-16
Inotrem–SEVERAL: investment, 201909 financing round Series B €39m led by Morningside Ventures 2019-09-12
Khanu Management–Austria (govt): investment, 201909 1st closing totalling €60m of KHAN Technology Transfer Fund I incl aws 2019-09-12
Khanu Management–EU (govt): investment, 201909 1st closing totalling €60m of KHAN Technology Transfer Fund I incl European Investment Fund 2019-09-12
Khanu Management–Max Planck: investment, 201909 1st closing totalling €60m of KHAN Technology Transfer Fund I incl Max Planck Foundation 2019-09-12
Khanu Management–SEVERAL: investment, 201909 1st closing €60m of KHAN Technology Transfer Fund I 2019-09-12
Orion Corp–Genedata: bioinformatics, 201909– supply license to Genedata Biologics as SaaS for large-molecule RnD to Orion Pharma 2019-09-11
Bayer–Minapharm: GlymaxX technology, 201909– license for use in cell line developm for cancer antibody candidate of Bayer 2019-09-10
Grünenthal–Mesoblast: cell therapy, 201909– strategic collab $15m upfront developm + commercialisation of MPC-06-ID in Europe + Lation America 2019-09-10
next pagenext page 1 2 3 ... 27 28 29 ... 33 34 35  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px

» top